Table 1.
Clinical and biological features of myelofibrosis associated lymphoma patients.
| N (%) | |
|---|---|
| Patients | 16 |
| Age (years) | |
| Median (range) | 62 (16–74) |
| Sex | |
| Male/female | 12/4 (75/25) |
| Lymphoma histology | |
| Low grade | 8 (50) |
| MCL | 3 |
| DLCL | 3 |
| others | 2 |
| B symptoms | |
| Positive | 11 (69) |
| negative | 5 |
| Splenomegaly | |
| yes | 8 (50) |
| no | 8 (50) |
| LDH level (UI/L) | |
| normal | 6 (38) |
| elevated | 10 (62) |
| WBC count | |
| median (range) (109/L) | 8.4 (3.0-20.7) |
| Hb level | |
| median (range) (g/dl) | 12 (8.4–15) |
| platelets count | |
| median (range) (109/L) | 165 (50–444) |
| Dacryocytes | |
| Positive/negative/na | 1/12/3 |
| Leucoerythrocytic features | |
| Positive/negative/na | 3/10/3 |
| FLIPI | |
| 0–1 | 1/5 (20) |
| >1 | 4/5 (80) |
| Myelofibrosis grading | |
| Mild | 9 (56) |
| Moderate | 6 (37) |
| Severe | 1 |
| N° lines chemotherapy | |
| 1–3 lines | 15 (93) |
| >3 lines | 1 |
| Overall response rate | 94% |
| Overall survival (months) | 72 |
DLCL: diffuse large cell lymphoma; FLIPI: follicular lymphoma international prognostic index; LDH: lactate dehydrogenase; MCL: mantle cell lymphoma; WBC: white blood cells; Hb: hemoglobin.